Amgen (AMGN) Phase 1 Data Supports Combo - Raymond James
Tweet Send to a Friend
Raymond James analyst Dane Leone reiterated an Outperform rating and $255.00 price target on Amgen (NASDAQ: AMGN) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


